Intelligent Bio Solutions Inc. (INBS) is a pioneering biotechnology company focused on delivering cutting-edge diagnostic solutions and biomarker-driven technologies, specifically designed for drug abuse testing and monitoring. Utilizing advanced scientific methodologies, INBS offers rapid and precise testing options that enhance clinical decision-making processes and improve patient outcomes. In a healthcare landscape increasingly reliant on innovative diagnostic tools, INBS is well-positioned to make substantial contributions to this evolving field, reinforcing its dedication to advancing healthcare quality and operational effectiveness.
| Revenue (TTM) | $3.91M |
| Gross Profit (TTM) | $1.85M |
| EBITDA | $-10.23M |
| Operating Margin | -277.30% |
| Return on Equity | -170.20% |
| Return on Assets | -57.30% |
| Revenue/Share (TTM) | $3.83 |
| Book Value | $4.48 |
| Price-to-Book | 0.93 |
| Price-to-Sales (TTM) | 2.60 |
| EV/Revenue | 0.855 |
| EV/EBITDA | -0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 45.50% |
| Shares Outstanding | $3.02M |
| Float | $2.16M |
| % Insiders | 2.83% |
| % Institutions | 6.01% |
Volatility is currently expanding
Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.
Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System, supporting its FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. The study was conducted in partnership with CenExel Clinical Research, Inc., following FDA guidance and ICH GCP (International Council for Harmonisation Good Clinical Practice) standards.
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. The study supports the Company's FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine.
Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation
Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Conference Details Date: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT Presentation Location: Track 7 – Donatello 3 Registration: Interested investors can register to attend here Webcast: Viewable here Booth: 413 The Company will be participating in one-on-one investor meetings throughout the event.
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end of July, 2026 NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The Company has partnered with nationwide clinical research site network, CenExel Clinical Research, Inc., to perform the study, which will evaluate the accuracy of the Intelligent Fingerprinting Drug Screening System when operated by intended end-users across multiple clinical sites.
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update. "The third quarter marked another period of strong commercial execution and revenue growth," said Harry Simeonidis, President and CEO at INBS.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INBS and any ticker you trade — then tracks every position and per-strategy win rate.
